Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
J9145 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan 1, 2017 In Use
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct 1, 2010 Jun 30, 2011 No Longer Used
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct 1, 2019 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
S0177 Levamisole Ergamisol 50 mg Immunotherapy Antiinfective Agent antihelminitic Yes 1990 2000 Jan 1, 2002 In Use
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Jul 11, 2023 In Use
J9031 Bacillus calmette-guerin substrain nice live antigen Theracys, BCG Vaccine Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 1991 Jul 1, 2019 No Longer Used
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb 12, 2004 Dec 31, 2004 No Longer Used
C9287 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2012 Dec 31, 2012 No Longer Used
J9042 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2013 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug 28, 2023 In Use
Q2056 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Sep 27, 2022 In Use
C9098 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Mar 25, 2022 Sep 27, 2022 No Longer Used
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan 1, 2016 In Use
J9303 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan 1, 2008 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan 1, 2002 In Use
C9073 Brexucabtagene autileucel Tecartus 2000000 Immunotherapy CAR-T CD19 No 2020 Jan 1, 2021 Apr 1, 2021 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 Apr 1, 2021 In Use
J9347 Tremelimumab-actl Imjudo 1mg Immunotherapy Monoclonal Antibody CTLA-4 No 2022 Jul 11, 2023 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.